The Global Diagnostics Partnering 2010-2017: Deal trends,
players, financials and forecasts report provides comprehensive understanding
and unprecedented access to the diagnostics partnering deals and agreements
entered into by the worlds leading healthcare companies
Description
The Global Diagnostics Partnering 2010-2017 report provides
comprehensive understanding and unprecedented access to the diagnostic
partnering agreements entered into by the worlds leading companies.
Comprehensive directory of diagnostic deals since 2010
- Diagnostic contract documents
- Diagnostic agreement terms
- Diagnostic agreement structure
- Top diagnostic deals by value
- Most active diagnostic dealmakers
This report provides details of the latest diagnostics
agreements announced in the healthcare sectors, covering:
- Companion Diagnostics
- Imaging
- CT
- Endoscope
- Molecular and nuclear
- MRI
- Ultrasound
- X-ray
- PET
- SPECT
- Angiography
- Fluroscopy
- Mammography
- In vitro diagnostics
- Molecular diagnostics
- Prognostics
- Theranostics
The report provides a detailed understanding and analysis of
how and why companies enter Diagnostics partnering deals. These deals tend to
be multicomponent, starting with collaborative R&D, and proceed to
commercialization of outcomes.
This report provides details of the latest Diagnostics
agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review
Diagnostics deal trends, key players, top deal values, as well as deal
financials, allowing the understanding of how, why and under what terms,
companies are entering Diagnostics partnering deals.
The report presents financial deal term values for
Diagnostics deals, listing by headline value, upfront payments, milestone
payments and royalties, enabling readers to analyse and benchmark the financial
value of deals.
The middle section of the report explores the leading
dealmakers in the Diagnostics partnering field; both the leading deal values
and most active Diagnostics dealmaker companies are reported allowing the
reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 3,600
online deal records of actual Diagnostics deals, as disclosed by the deal
parties, are included towards the end of the report in a directory format – by
company A-Z, stage of development, deal type, therapy focus, and technology
type - that is easy to reference. Each deal record in the report links via
Weblink to an online version of the deal.
In addition, where available, records include contract
documents as submitted to the Securities Exchange Commission by companies and
their partners. Whilst many companies will be seeking details of the payment
clauses, the devil is in the detail in terms of how payments are triggered –
contract documents provide this insight where press releases and databases do
not.
The initial chapters of this report provide an orientation
of Diagnostics dealmaking. Chapter 1 provides an introduction to the report,
whilst chapter 2 provides an overview of the trends in Diagnostics dealmaking
since 2010, including details of headline, upfront, milestone and royalty
terms.
Chapter 3 provides a review of the leading Diagnostics deals
since 2010. Deals are listed by headline value. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25
most active companies in Diagnostics dealmaking with a brief summary followed
by a comprehensive listing of Diagnostics deals announded by that company, as
well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of
Diagnostics partnering deals signed and announced since Jan 2010, where a
contract document is available in the public domain. Each deal title links via
Weblink to an online version of the deal record and contract document,
providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of
Diagnostics partnering deals signed and announced since Jan 2010. The chapter
is organized by specific Diagnostics technology type. Each deal title links via
Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized
by Diagnostics partnering company A-Z, stage of development, deal type, and
therapy focus. Each deal title links via Weblink to an online version of the
deal record and where available, the contract document, providing easy access
to each deal on demand.
The report also includes numerous tables and figures that
illustrate the trends and activities in Diagnostics partnering and dealmaking
since 2010.
In conclusion, this report provides everything a prospective
dealmaker needs to know about partnering in the research, development and
commercialization of Diagnostics technologies and products.
Key benefits
Global Diagnostics Partnering 2010-2017: Deal trends, players,
financials and forecasts provides the reader with the following key benefits:
- In-depth understanding of Diagnostics deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Diagnostics agreements with numerous real life case studies
- Detailed access to actual Diagnostics contracts entered into by leading biopharma companies
- Identify most active Diagnostics dealmakers since 2010
- Insight into terms included in a Diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Diagnostics Partnering 2010-2017: Deal trends,
players, financials and forecasts is intended to provide the reader with an
in-depth understanding and access to Diagnostics trends and structure of deals
entered into by leading companies worldwide.
Diagnostics Partnering Terms and Agreements includes:
- Trends in Diagnostics dealmaking in the biopharma industry since 2010
- Analysis of Diagnostics deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life Diagnostics deals
- Access to Diagnostics contract documents
- Leading Diagnostics deals by value since 2010
- Most active Diagnostics dealmakers since 2010
In Global Diagnostics Partnering 2010-2017: Deal trends,
players, financials and forecasts, the available deals are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
- Technology type
The Global Diagnostics Partnering 2010-2017: Deal trends,
players, financials and forecasts report provides comprehensive access to
available deals and contract documents for over 3,600 Diagnostics deals.
Analyzing actual contract agreements allows assessment of
the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Global Diagnostics Partnering 2010-2017 provides the reader
with the following key benefits:
- In-depth understanding of Diagnostics deal trends since 2010
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of Diagnostics agreements with numerous real life case studies
- Detailed access to actual Diagnostics contracts entered into by leading biopharma companies
- Identify most active Diagnostics dealmakers since 2010
- Insight into terms included in a Diagnostics partnering agreement, with real world examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 1000 pages “Global Diagnostics
Partnering 2010-2016: Deal trends, players, financials and forecasts” report covers Executive
Summary, Introduction, Trends in Diagnostics dealmaking, Leading Diagnostics
deals, Most active Diagnostics dealmakers, Diagnostics contracts dealmaking
directory, Diagnostics dealmaking by technology type, Partnering resource
center, Appendices.
For
more information Visit at: http://mrr.cm/UYq
Related Reports;
Global
Pharmaceutical Partnering Terms and Agreements 2010-2016: Deal trends, players
and financials - Visit at - http://mrr.cm/UYc
Global
Drug Delivery Partnering 2010-2016: Deal trends, players and financials - Visit
at - http://mrr.cm/UYp
No comments:
Post a Comment
Note: only a member of this blog may post a comment.